Holen Sie sich die Stockscreener-App
463.03
1.87%
8.4672
Schlusskurs vom Vortag:
$454.56
Offen:
$453.9
24-Stunden-Volumen:
612.85K
Relative Volume:
0.57
Marktkapitalisierung:
$61.15B
Einnahmen:
$3.21B
Nettoeinkommen (Verlust:
$43.57M
KGV:
1,925.27
EPS:
0.2405
Netto-Cashflow:
$221.36M
1W Leistung:
+7.74%
1M Leistung:
+1.54%
6M Leistung:
+51.28%
1J Leistung:
+83.02%
1-Tages-Spanne:
$453.00
$472.48
1-Wochen-Bereich:
$430.27
$472.48
52-Wochen-Spanne:
$205.87
$495.55
Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile
Firmenname
Alnylam Pharmaceuticals Inc
Sektor
Branche
Telefon
(617) 551-8200
Adresse
675 WEST KENDALL STREET, CAMBRIDGE, MA
Vergleichen Sie ALNY mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALNY
Alnylam Pharmaceuticals Inc
|
462.83 | 60.05B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
VRTX
Vertex Pharmaceuticals Inc
|
433.54 | 107.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.43 | 78.84B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
918.03 | 55.10B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
207.62 | 45.09B | 447.02M | -1.18B | -906.14M | -6.1812 |
Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-04 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2025-08-04 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2025-07-30 | Fortgesetzt | Raymond James | Outperform |
| 2025-07-21 | Eingeleitet | Truist | Buy |
| 2025-03-31 | Eingeleitet | Redburn Atlantic | Buy |
| 2025-03-24 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-11-12 | Herabstufung | Wolfe Research | Peer Perform → Underperform |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-08-16 | Hochstufung | Goldman | Neutral → Buy |
| 2024-02-16 | Herabstufung | Goldman | Buy → Neutral |
| 2024-02-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Equal Weight |
| 2023-10-11 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2023-09-29 | Eingeleitet | Raymond James | Outperform |
| 2023-05-05 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-26 | Eingeleitet | SMBC Nikko | Neutral |
| 2023-03-21 | Eingeleitet | Bernstein | Outperform |
| 2023-01-18 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-09-09 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2022-06-27 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-06-07 | Eingeleitet | William Blair | Outperform |
| 2022-04-25 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-03-01 | Eingeleitet | Citigroup | Buy |
| 2022-02-03 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-01-03 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-11-22 | Hochstufung | Goldman | Neutral → Buy |
| 2021-11-22 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-01 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-10-04 | Hochstufung | UBS | Neutral → Buy |
| 2021-08-04 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-02-22 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-02-12 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-02-12 | Bestätigt | H.C. Wainwright | Buy |
| 2021-01-25 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-30 | Fortgesetzt | Berenberg | Hold |
| 2020-09-08 | Eingeleitet | Citigroup | Buy |
| 2020-08-11 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2020-05-13 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2020-05-07 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-04-24 | Fortgesetzt | Evercore ISI | Outperform |
| 2020-03-19 | Eingeleitet | Berenberg | Buy |
| 2019-12-19 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-11-20 | Eingeleitet | Oppenheimer | Outperform |
| 2019-11-13 | Eingeleitet | BofA/Merrill | Buy |
| 2019-05-23 | Fortgesetzt | Goldman | Neutral |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2019-03-06 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2019-03-05 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2019-01-23 | Eingeleitet | UBS | Neutral |
| 2018-10-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-08-13 | Bestätigt | Stifel | Buy |
| 2018-08-07 | Hochstufung | Stifel | Hold → Buy |
| 2018-05-04 | Bestätigt | Stifel | Hold |
| 2018-03-28 | Eingeleitet | Evercore ISI | In-line |
Alle ansehen
Alnylam Pharmaceuticals Inc Aktie (ALNY) Neueste Nachrichten
Here's How Much You Would Have Made Owning Alnylam Pharmaceuticals Stock In The Last 20 Years - Benzinga
Options Movement At Alnylam Pharmaceuticals: Yvonne Greenstreet Exercises Worth $1.72M - Benzinga
How Alnylam Pharmaceuticals Inc. stock benefits from tech adoptionJuly 2025 Reactions & Long-Term Growth Plans - Newser
Can Alnylam Pharmaceuticals Inc. (DUL) stock sustain institutional flowsMarket Risk Summary & Technical Pattern Based Signals - Newser
Is Alnylam Pharmaceuticals Inc. (DUL) stock prepared for digital transitionQuarterly Profit Review & Fast Exit and Entry Strategy Plans - Newser
Will Alnylam Pharmaceuticals Inc. (DUL) stock benefit from mergersPortfolio Return Report & Low Volatility Stock Suggestions - Newser
What hedge fund activity signals for Alnylam Pharmaceuticals Inc. stockGap Down & Risk Adjusted Buy and Sell Alerts - Newser
Can Alnylam Pharmaceuticals Inc. (DUL) stock sustain revenue momentumMarket Movement Recap & AI Powered Market Entry Strategies - Newser
How Alnylam Pharmaceuticals Inc. (DUL) stock reacts to fiscal policiesPortfolio Return Summary & High Conviction Investment Ideas - Newser
Is Alnylam Pharmaceuticals Inc. (DUL) stock good for wealth creationJuly 2025 Catalysts & High Accuracy Swing Trade Signals - Newser
Is Alnylam Pharmaceuticals Inc. (DUL) stock a fit for income portfoliosExit Point & Fast Exit and Entry Trade Guides - Newser
Will Alnylam Pharmaceuticals Inc. stock benefit from commodity prices2025 Key Highlights & Technical Pattern Alert System - Newser
CRH, Vertiv, Ares, Alnylam Could Be Added to S&P 500 Friday in Rebalancing - Barron's
Spotlight On Alnylam Pharmaceuticals And 2 Other Stocks Possibly Trading Below Fair Value - Yahoo Finance
Alnylam Pharmaceuticals, Inc. (0HD2.L) Stock Price, News, Quote & History - Yahoo! Finance Canada
The Bull Case For Alnylam Pharmaceuticals (ALNY) Could Change Following Raised Sales Guidance for Vutrisiran - simplywall.st
What's Going On With Alnylam Stock On Friday? - Benzinga
Can Alnylam Pharmaceuticals Inc. stock beat market expectations this quarterWeekly Earnings Recap & Technical Confirmation Trade Alerts - moha.gov.vn
Alnylam Pharmaceuticals Reports Strong TTR Growth Amid Challenges - MSN
IPO Launch: Why Alnylam Pharmaceuticals Inc. stock could be next big winnerMarket Risk Analysis & High Conviction Buy Zone Alerts - moha.gov.vn
ETFs Investing in Alnylam Pharmaceuticals, Inc Stocks - TradingView
Thanksgiving: Top 10 Most Innovative BioPharma Drugs In Phase 3 - Seeking Alpha
A Look at Alnylam Pharmaceuticals's Valuation Following Raised Sales Guidance on Vutrisiran Outperformance - simplywall.st
Here’s What Boosted Alnylam Pharmaceuticals (ALNY) in Q3 - MSN
Backdoor AI Beneficiary Yields 8.8%, Trades at 13% Discount - Investing.com
Alnylam’s TTR Franchise Drives Big Revenue Growth And Raises Guidance - Finimize
MoA Mid Cap Growth Fund's Alnylam Pharmaceuticals Inc(ALNY) Holding History - GuruFocus
Alnylam Pharmaceuticals (ALNY): Assessing Valuation After Recent Share Price Pullback - Yahoo Finance
Is Alnylam Pharmaceuticals Stock Justified After 73.9% Surge and Clinical Trial Milestones? - simplywall.st
Small Interfering RNA (siRNA) Therapeutics Market 2025: - openPR.com
Here's How Much You Would Have Made Owning Alnylam Pharmaceuticals Stock In The Last 15 Years - Benzinga
Alnylam's ATTR cardiomyopathy drug backed for NHS use - pharmaphorum
NICE Final Draft Guidance backs Alnylam’s Amvuttra - The Pharma Letter
Why Alnylam Pharmaceuticals Inc. (DUL) stock attracts wealthy investorsJuly 2025 Institutional & Expert Approved Trade Ideas - newser.com
Alnylam Pharmaceuticals Faces Weak Start with 6.56% Gap Down Amid Market Concerns - Markets Mojo
UK's drug-cost watchdog recommends Alnylam's heart disease drug - Reuters
UK’s drug-cost watchdog recommends Alnylam’s heart disease drug - The Mighty 790 KFGO
High-Flying Biotech Stock Sets Up After 96% Pop; Profitability In Sight As Key Drug Sales Double - MSN
Is Alnylam Pharmaceuticals Inc. stock cheap at current valuationJuly 2025 Decliners & High Return Stock Watch Alerts - newser.com
Will Alnylam Pharmaceuticals Inc. (DUL) stock sustain bullish trend into 2025 - newser.com
Will Alnylam Pharmaceuticals Inc. stock deliver consistent dividendsTrade Analysis Report & Daily Growth Stock Investment Tips - newser.com
Is Alnylam Pharmaceuticals Inc. stock a defensive play in 2025Weekly Profit Summary & Free Weekly Chart Analysis and Trade Guides - newser.com
Regression analysis insights on Alnylam Pharmaceuticals Inc. performance2025 Top Gainers & Reliable Volume Spike Alerts - newser.com
Will Alnylam Pharmaceuticals Inc. continue its uptrendEarnings Miss & Smart Money Movement Tracker - newser.com
VP Fitzgerald Sells 12,128 ($5.5M) Of Alnylam Pharmaceuticals Inc [ALNY] - TradingView
[Form 4] ALNYLAM PHARMACEUTICALS, INC. Insider Trading Activity - Stock Titan
How risky is Alnylam Pharmaceuticals Inc. (DUL) stock compared to peers2025 Top Decliners & Expert Approved Trade Ideas - newser.com
How dovish Fed policy supports Alnylam Pharmaceuticals Inc. (DUL) stockQuarterly Profit Report & Reliable Intraday Trade Alerts - newser.com
Transcript : Alnylam Pharmaceuticals, Inc. Presents at Jefferies London Healthcare Conference 2025, Nov-19-2025 11 - MarketScreener
Finanzdaten der Alnylam Pharmaceuticals Inc-Aktie (ALNY)
Umsatz
Nettogewinn
Free Cashflow
ENV
Alnylam Pharmaceuticals Inc-Aktie (ALNY) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Fitzgerald Kevin Joseph | CSO & EVP, Head of Research |
Nov 17 '25 |
Option Exercise |
119.13 |
8,161 |
972,220 |
33,392 |
| Fitzgerald Kevin Joseph | CSO & EVP, Head of Research |
Nov 17 '25 |
Sale |
452.18 |
12,128 |
5,483,990 |
21,264 |
2.25%
1.01%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):